|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Gleevec
|
|
gptkbp:activities
|
tyrosine kinase inhibitor
|
|
gptkbp:approves
|
gptkb:2001
|
|
gptkbp:brand
|
gptkb:Gleevec
gptkb:Glivec
|
|
gptkbp:clinical_trial
|
Phase II
Phase III
Phase I
|
|
gptkbp:contraindication
|
severe liver impairment
hypersensitivity to imatinib
|
|
gptkbp:developed_by
|
gptkb:Novartis
|
|
gptkbp:dosage_form
|
oral tablet
oral solution
|
|
gptkbp:excretion
|
urine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
imatinib
|
|
gptkbp:indication
|
gptkb:Philadelphia_chromosome-positive_leukemia
gptkb:myelodysplastic_syndromes
gptkb:metastatic_melanoma
|
|
gptkbp:ingredients
|
C29 H31 N7 O2 S
|
|
gptkbp:interacts_with
|
CY P2 C19
CY P3 A4
|
|
gptkbp:is_atype_of
|
L01 X E03
|
|
gptkbp:is_available_on
|
gptkb:software_framework
gptkb:tablet
|
|
gptkbp:is_used_for
|
gptkb:chronic_myeloid_leukemia
gptkb:gastrointestinal_stromal_tumors
|
|
gptkbp:lifespan
|
15-20 hours
|
|
gptkbp:manager
|
oral
|
|
gptkbp:marketed_as
|
gptkb:2001
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:research_areas
|
oncology
hematology
pharmacology
|
|
gptkbp:side_effect
|
gptkb:fandom
fatigue
headache
nausea
gastrointestinal bleeding
diarrhea
rash
dry skin
insomnia
cardiovascular events
skin reactions
weight gain
peripheral neuropathy
pulmonary hypertension
hypothyroidism
thrombocytopenia
muscle cramps
edema
hepatotoxicity
hyperglycemia
neutropenia
nail changes
vision changes
musculoskeletal pain
|
|
gptkbp:targets
|
gptkb:BCR-ABL_fusion_protein
|
|
gptkbp:treatment
|
gptkb:chronic_myeloid_leukemia
gptkb:gastrointestinal_stromal_tumors
|
|
gptkbp:type_of
|
152459-95-5
|